Illumina Inc. (ILMN)$144.41
Market Cap: 12.37 BCurrency: USD
Research Snapshot
Static fundamentals, valuation context, and investor signals for Illumina Inc. (ILMN).
HEALTHCARE
DIAGNOSTICS & RESEARCH
DCF ready
Valuation
11.8x
EV/FCF, 8.5% FCF yield
Quality
31.2%
ROIC, 21.4% FCF margin
Growth
6.0%
5Y sales (revenue) CAGR
Balance sheet
0.0x
Debt/equity, 2.1x current ratio
Superinvestors
2
Top: Triple Frond Partners (3.9%)
Strengths to research
- Return on equity is strong at 31.2%.
- Free cash flow margin is healthy at 21.4%.
- Debt/equity looks manageable at 0.0x.
- 10 annual periods are available for trend analysis.
Watchouts
No major valuation, balance sheet, or growth watchouts were detected by the static screen.
Annual data: 10 periods
Quarterly data: 23 periods
Stock snapshot: May 25, 2026
Static dataset: May 25, 2026
Quality Scorecard
Build-time composite score for ILMN.
Grade C
63
/ 100
Peer Comparison
Target stock against 8 market-cap comparable peers.
Heat map: red worst to green best
| ILMN Target | Illumina Inc. | $12.4B | 26.5x | 11.8x | 31.2% | 6.0% | 21.4% | 66.1% | -1.3x | N/A |
| ERFSF | Eurofins Scientific SE | $11.5B | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| ICLR | ICON plc | $11.4B | 12.3x | 9.7x | 8.3% | 24.2% | 13.5% | N/A | -0.3x | N/A |
| MEDP | Medpace Holdings Inc. | $8.6B | 28.3x | 11.9x | 98.3% | 22.3% | 26.9% | N/A | -0.9x | N/A |
| DGX | Quest Diagnostics | $19.8B | 22.3x | 18.5x | 7.7% | 3.2% | 12.3% | N/A | 2.5x | N/A |
| LH | Labcorp Holdings Inc. | $20.7B | 24.8x | 16.7x | 10.2% | -0.0% | 8.6% | 28.8% | -0.3x | N/A |
| NTRA | Natera Inc. | $21.4B | -133.7x | 186.2x | -12.2% | 42.6% | 4.7% | N/A | N/A | N/A |
| MTD | Mettler-Toledo International Inc. | $22.7B | 26.2x | 29.2x | 42.1% | 5.5% | 21.1% | 59.4% | N/A | N/A |
| CRL | Charles River Labs | $5.9B | -55.1x | 10.9x | -4.6% | 6.5% | 12.9% | N/A | -0.5x | N/A |
Financial Charts
No financial data available for ILMN (annual).
2 superinvestors own ILMN
Current quarter ownership and quarter-over-quarter share changes.
Superinvestor ownership
| Fund | Shares | Value | % Portfolio | QoQ Change |
|---|---|---|---|---|
| Samantha McLemore Patient Capital Management | 544,780 | $67M | 2.50% | 0.0% |
| Triple Frond Partners Triple Frond Partners | 306,460 | $38M | 3.92% | 0.0% |